These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
719 related articles for article (PubMed ID: 23948348)
1. Effect of initial treatment strategy on survival of patients with advanced-stage Hodgkin's lymphoma: a systematic review and network meta-analysis. Skoetz N; Trelle S; Rancea M; Haverkamp H; Diehl V; Engert A; Borchmann P Lancet Oncol; 2013 Sep; 14(10):943-52. PubMed ID: 23948348 [TBL] [Abstract][Full Text] [Related]
2. Comparison of first-line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma. Skoetz N; Will A; Monsef I; Brillant C; Engert A; von Tresckow B Cochrane Database Syst Rev; 2017 May; 5(5):CD007941. PubMed ID: 28541603 [TBL] [Abstract][Full Text] [Related]
3. BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group. Diehl V; Franklin J; Hasenclever D; Tesch H; Pfreundschuh M; Lathan B; Paulus U; Sieber M; Rueffer JU; Sextro M; Engert A; Wolf J; Hermann R; Holmer L; Stappert-Jahn U; Winnerlein-Trump E; Wulf G; Krause S; Glunz A; von Kalle K; Bischoff H; Haedicke C; Duehmke E; Georgii A; Loeffler M J Clin Oncol; 1998 Dec; 16(12):3810-21. PubMed ID: 9850026 [TBL] [Abstract][Full Text] [Related]
4. Spermatogenesis in Hodgkin's lymphoma patients: a retrospective study of semen quality before and after different chemotherapy regimens. Paoli D; Rizzo F; Fiore G; Pallotti F; Pulsoni A; Annechini G; Lombardo F; Lenzi A; Gandini L Hum Reprod; 2016 Feb; 31(2):263-72. PubMed ID: 26705149 [TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of first-line treatment options for patients with advanced-stage Hodgkin lymphoma: a modelling study. Vijenthira A; Chan K; Cheung MC; Prica A Lancet Haematol; 2020 Feb; 7(2):e146-e156. PubMed ID: 31948928 [TBL] [Abstract][Full Text] [Related]
6. Comparative effectiveness of different chemotherapy regimens of advanced-stage Hodgkin lymphoma in adults: a network meta-analysis. Zhang T; Yao Y; Feng F; Zhao W; Tian J; Zhou C; Wang X; Dong S; Li J; Qi L; Sun C Cancer Manag Res; 2018; 10():6017-6028. PubMed ID: 30538551 [TBL] [Abstract][Full Text] [Related]
7. Comparison of chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for patients with early unfavourable or advanced stage Hodgkin lymphoma. Bauer K; Skoetz N; Monsef I; Engert A; Brillant C Cochrane Database Syst Rev; 2011 Aug; (8):CD007941. PubMed ID: 21833963 [TBL] [Abstract][Full Text] [Related]
8. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. Diehl V; Franklin J; Pfreundschuh M; Lathan B; Paulus U; Hasenclever D; Tesch H; Herrmann R; Dörken B; Müller-Hermelink HK; Dühmke E; Loeffler M; N Engl J Med; 2003 Jun; 348(24):2386-95. PubMed ID: 12802024 [TBL] [Abstract][Full Text] [Related]
9. Intensified treatment of patients with early stage, unfavourable Hodgkin lymphoma: long-term follow-up of a randomised, international phase 3 trial of the German Hodgkin Study Group (GHSG HD14). Gillessen S; Plütschow A; Fuchs M; Markova J; Greil R; Topp MS; Meissner J; Zijlstra JM; Eichenauer DA; Bröckelmann PJ; Diehl V; Borchmann P; Engert A; von Tresckow B Lancet Haematol; 2021 Apr; 8(4):e278-e288. PubMed ID: 33770483 [TBL] [Abstract][Full Text] [Related]
10. Eight Cycles of ABVD Versus Four Cycles of BEACOPPescalated Plus Four Cycles of BEACOPPbaseline in Stage III to IV, International Prognostic Score ≥ 3, High-Risk Hodgkin Lymphoma: First Results of the Phase III EORTC 20012 Intergroup Trial. Carde P; Karrasch M; Fortpied C; Brice P; Khaled H; Casasnovas O; Caillot D; Gaillard I; Bologna S; Ferme C; Lugtenburg PJ; Morschhauser F; Aurer I; Coiffier B; Meyer R; Seftel M; Wolf M; Glimelius B; Sureda A; Mounier N J Clin Oncol; 2016 Jun; 34(17):2028-36. PubMed ID: 27114593 [TBL] [Abstract][Full Text] [Related]
11. Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPP Borchmann P; Haverkamp H; Lohri A; Mey U; Kreissl S; Greil R; Markova J; Feuring-Buske M; Meissner J; Dührsen U; Ostermann H; Keller U; Maschmeyer G; Kuhnert G; Dietlein M; Kobe C; Eich H; Baues C; Stein H; Fuchs M; Diehl V; Engert A Lancet Oncol; 2017 Apr; 18(4):454-463. PubMed ID: 28236583 [TBL] [Abstract][Full Text] [Related]
12. Can MOPP be replaced in the treatment of advanced Hodgkin's disease? Canellos GP Semin Oncol; 1990 Feb; 17(1 Suppl 2):2-6. PubMed ID: 1689509 [TBL] [Abstract][Full Text] [Related]
13. Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin's lymphoma: final results of the German Hodgkin's Lymphoma Study Group Trial HD5. Sieber M; Tesch H; Pfistner B; Rueffer U; Lathan B; Brosteanu O; Paulus U; Koch T; Pfreundschuh M; Loeffler M; Engert A; Josting A; Wolf J; Hasenclever D; Franklin J; Duehmke E; Georgii A; Schalk KP; Kirchner H; Doelken G; Munker R; Koch P; Herrmann R; Greil R; Anselmo AP; Diehl V J Clin Oncol; 2002 Jan; 20(2):476-84. PubMed ID: 11786577 [TBL] [Abstract][Full Text] [Related]
14. Long-Term Results of the HD2000 Trial Comparing ABVD Versus BEACOPP Versus COPP-EBV-CAD in Untreated Patients With Advanced Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi. Merli F; Luminari S; Gobbi PG; Cascavilla N; Mammi C; Ilariucci F; Stelitano C; Musso M; Baldini L; Galimberti S; Angrilli F; Polimeno G; Scalzulli PR; Ferrari A; Marcheselli L; Federico M J Clin Oncol; 2016 Apr; 34(11):1175-81. PubMed ID: 26712220 [TBL] [Abstract][Full Text] [Related]
15. ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi. Gobbi PG; Levis A; Chisesi T; Broglia C; Vitolo U; Stelitano C; Pavone V; Cavanna L; Santini G; Merli F; Liberati M; Baldini L; Deliliers GL; Angelucci E; Bordonaro R; Federico M; J Clin Oncol; 2005 Dec; 23(36):9198-207. PubMed ID: 16172458 [TBL] [Abstract][Full Text] [Related]
16. Long-term follow-up analysis of HD9601 trial comparing ABVD versus Stanford V versus MOPP/EBV/CAD in patients with newly diagnosed advanced-stage Hodgkin's lymphoma: a study from the Intergruppo Italiano Linfomi. Chisesi T; Bellei M; Luminari S; Montanini A; Marcheselli L; Levis A; Gobbi P; Vitolo U; Stelitano C; Pavone V; Merli F; Liberati M; Baldini L; Bordonaro R; Pesce EA; Federico M J Clin Oncol; 2011 Nov; 29(32):4227-33. PubMed ID: 21990405 [TBL] [Abstract][Full Text] [Related]
17. Treatment of advanced Hodgkin's disease with chemotherapy--comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: a report from the National Cancer Institute of Canada clinical trials group. Connors JM; Klimo P; Adams G; Burns BF; Cooper I; Meyer RM; O'Reilly SE; Pater J; Quirt I; Sadura A; Shustik C; Skillings J; Sutcliffe S; Verma S; Yoshida S; Zee B J Clin Oncol; 1997 Apr; 15(4):1638-45. PubMed ID: 9193364 [TBL] [Abstract][Full Text] [Related]
18. What is the treatment of choice for advanced-stage Hodgkin's lymphoma: ABVD, Stanford V, or BEACOPP? Hehn ST; Miller TP Curr Hematol Rep; 2004 Jan; 3(1):17-26. PubMed ID: 14695845 [TBL] [Abstract][Full Text] [Related]
19. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. Engert A; Diehl V; Franklin J; Lohri A; Dörken B; Ludwig WD; Koch P; Hänel M; Pfreundschuh M; Wilhelm M; Trümper L; Aulitzky WE; Bentz M; Rummel M; Sezer O; Müller-Hermelink HK; Hasenclever D; Löffler M J Clin Oncol; 2009 Sep; 27(27):4548-54. PubMed ID: 19704068 [TBL] [Abstract][Full Text] [Related]
20. ABVD or BEACOPP Fermé C; Thomas J; Brice P; Casasnovas O; Vranovsky A; Bologna S; Lugtenburg PJ; Bouabdallah R; Carde P; Sebban C; Eghbali H; Salles G; van Imhoff GW; Thyss A; Noordijk EM; Reman O; Lybeert MLM; Janvier M; Spina M; Audhuy B; Raemaekers JMM; Delarue R; Anglaret B; de Weerdt O; Marjanovic Z; Tersteeg RJHA; de Jong D; Brière J; Henry-Amar M; ; Eur J Cancer; 2017 Aug; 81():45-55. PubMed ID: 28601705 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]